Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2011. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the Company's issued share capital as of February 28, 2011:
- Total Issued Ordinary Shares: 5,670,877,693 (25p each with voting rights).
- Treasury Shares: 484,034,284 Ordinary shares held in Treasury.
- Total Voting Rights: 5,186,843,409.
No other material changes to operations or financial position are disclosed in this text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of share capital figures for shareholder notification purposes.
Investor Verification Checklist
- Verify the total number of voting rights (5,186,843,409) for compliance with Financial Services Authority Disclosure and Transparency Rules.
- Confirm the number of shares held in Treasury (484,034,284) to calculate the correct denominator for interest notifications.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.